DXVX Forges Historic Partnership for mRNA Cancer Vaccine

In a groundbreaking move, Dx&Vx (DXVX), a pioneering Korean biotechnology company, has entered into a monumental agreement with a U.S. biotech firm, marking a significant milestone in the fight against cancer. The deal, valued at approximately 300 billion won, focuses on the joint development and technology transfer of an innovative mRNA cancer vaccine.

Unprecedented Financial and Therapeutic Potential

The agreement not only underscores the vaccine's superior anti-cancer effects, as demonstrated in phase 2b clinical trials, but also outlines a lucrative revenue-sharing model post-commercialization. DXVX is set to receive milestone payments totaling around 300 billion won, with sales milestones projected to surpass 1.3 trillion won over 15 years.

Collaborative Path to Global Impact

While DXVX retains the lead in R&D, including clinical trials and production, its U.S. partner will spearhead global regulatory approvals and commercialization efforts. This partnership not only accelerates the vaccine's journey to market but also sets a precedent for future collaborations in DXVX's pipeline.

CEO Kwon Gyu-chan expressed optimism about the deal's ripple effect on ongoing negotiations, highlighting its strategic importance to the company's growth and the broader biotech landscape.